VIRGIN PULSE ANNOUNCES INDUSTRY-LEADING GDPR COMPLIANCE
Virgin Pulse Extends the GDPR's Strong Data Privacy Rights to All Clients and Members Across the Globe
PROVIDENCE, R.I., May 25, 2018 (GLOBE NEWSWIRE) -- Virgin Pulse, the leading global provider of digital employee health, wellbeing and engagement solutions, today announced that it has achieved compliance with the EU General Data Protection Regulation (GDPR) for the Virgin Pulse platform. The company has also appointed Associate Counsel Beatrice Botti as Data Protection Officer (DPO) to oversee the Virgin Pulse privacy program.
With this achievement, Virgin Pulse leads the market as the first company in the wellbeing and engagement industry to fully meet the comprehensive standards of the new GDPR data privacy law. The company has completed a thorough review of its internal data collection, storage and handling processes and implemented enhancements to achieve GDPR compliance and give all Virgin Pulse customers and members greater control over their personal data.
The GDPR is the first major law to replace and address shortcomings and gaps in the 1995 Data Protection Directive 95/46/EC including enforcement, liabilities, documenting processes, risk assessments, notification in case of a breach. This new regulation also strengthens rules for data minimization. As a global organization with more than 570 clients, hundreds of thousands of users and broad operations in the EU, Virgin Pulse has been focused since early 2017 on ensuring GDPR compliance by the May 25, 2018 deadline.
"Member privacy is at the center of our strategic priorities. Securing and protecting client and member data has never been more important than it is today, and we are proud to be setting a strong example in this area," said David Osborne, CEO of Virgin Pulse. "Achieving compliance with the GDPR is a rigorous process, one we have been actively and diligently working towards over the past year. We believe that all of our clients and members around the world should benefit from the same strong privacy rights and best practices, and have gone above and beyond to implement the GDPR as the Virgin Pulse standard for all clients and members, not just those located in the EU."
To achieve this compliance, Virgin Pulse conducted a comprehensive audit of its member policies and made revisions to ensure the language and tone are clear and understandable. All members are prompted to review and accept the redrafted policies and expressly consent to Virgin Pulse's privacy practices to participate in any of the programs. As part of this process, the company's product design, software development and implementation processes reflect a Privacy by Design philosophy. These embedded processes allow members to withdraw consent at any time, and grant members broad rights to request access, correct or delete their data.
With more than 3,200 clients, including 20 percent of the Global Fortune 500, and 2.1 million members across 190 countries, Virgin Pulse is the only truly global employee wellbeing and engagement provider in the market. Available today in 18 languages, Virgin Pulse has designed and developed its products to meet the needs of global organizations, and will continue to invest in its infrastructure and lead the industry in data privacy and security. The company's GDPR efforts strengthen an existing foundation of data privacy and information security. Virgin Pulse's Information Security Management System is also certified against the ISO 27001:2013, a robust and comprehensive global information security standard, and the EU-U.S. and Swiss-U.S. Privacy Shield Frameworks.
About Virgin Pulse
Virgin Pulse, a leading provider of technology solutions that promote employee and wellbeing and engagement, helps employers create workforces that are happier, healthier and more productive. The company's modern, mobile-first platform delivers personalized user experiences that utilize gamification to engage users in building habits that inspire measurable and sustainable change across individuals and organizations. By helping employees thrive at work and in all aspects of life, Virgin Pulse is helping change lives and businesses around the world for good. To learn more, visit www.virginpulse.com.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Virgin Pulse via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details19.7.2019 21:00:00 CEST | Press release
Amsterdam, 19 July 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") reports the repurchases made under its share repurchase program announced on 8 April 2019 and effective from 9 April 2019. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period 15 July 2019 through 19 July 2019 can be found in the bottom half of the table below. Further detailed information regarding both the progress of the share repurchase program and the overall trades made on a daily basis can be accessed via the Investors section of the Company’s website, or clicking the following link: https://amg-nv.com/investors/share-buyback/ Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount in Shares 2,915,630 Cumulative Repurchase Amount EUR 63,511,098 Cumulative Quantity Repurchased 2,534,054 Cumulative Average Repurchase Price EUR 25.06 Start Date 9 April
Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CEST | Press release
Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the
Banks net position in the Riksbank19.7.2019 16:47:00 CEST | Press release
JUL 19, 2019 SEK MILLION LENDING BORROWING 277
Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CEST | Pressemelding
Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til email@example.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans
Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CEST | Press release
Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to firstname.lastname@example.org. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A
Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CEST | Pressemelding
STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have